In MM we showed that chondroitin sulphate proteoglycan 4 (CSPG4), belonging to the same family of CD44, is expressed in MM cell and biopsies, and monoclonal antibodies against CSPG4 significantly reduced MM cell motility, migration, invasiveness, and anchorage-independent growth. This evidence concerns the gene CSPG4 and Miyoshi myopathy.